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ABSTRACT Mammalian embryonic stem cells (ESC) have a number of specific properties that make them a unique 
object of fundamental and applied studies. In culture, ESC can remain in an infinitely undifferentiated state and dif-
ferentiate into descendants of all three germ layers – ectoderm, endoderm, and mesoderm – that is, they can poten-
tially produce more than 200 cell types comprising the body of an adult mammal. These properties of ESC are refered 
to as self-renewal and pluripotency. In this review, the basic signal pathways implicated in the maintenance of ESC 
pluripotency are considered. The major genes comprising a subsystem of “internal regulators of pluripotency,” their 
protein products and regulators, are characterized, and interaction with other factors is described as well. The role of 
epigenetic mechanisms and microRNAs in the system of ESC self-renewal and pluripotency, as well as the relationship 
between pluripotency and X-chromosome inactivation in female mammals, is discussed.
KEYWORDS: embryonic stem cells, pluripotency, transcription factors, X-chromosome inactivation
ABBREVIATIONS: ESC – embryonic stem cell, mESC – murine ESC, hESC – human ESC, TSC – trophoblast stem cell, 
iPSC – induced pluripotent stem cell, ICM – inner cell mass, HCNE – highly conserved non-coding element
MAMMALIAN EMBRYOGENESIS AND STEM CELLS. 
PLURIPOTENT CELLS in vivo AND in vitro
Development of any mammal begins from a single cell, 
called the zygote. Its successive division and differen-
tiation of daughter cells eventually results in the for-
mation of an organism composed of more than 200 cell 
types, each executing a specific function via the forma-
tion of tissues and organs in which different cell types 
interact with each other. These functional, biochemi-
cal, and physiological specificities of distinct cell types 
depend on the characteristic pattern of gene expres-
sion. All the diverse forms of RNA transcribed in the 
cell nucleus are called “transcriptome,” which (unlike 
genome) is distinctive of the cell type and differs in dif-
ferent cell types within the body. The cell transcrip-
tome is determined by a tight interaction between the 
genetic and epigenetic systems. The former includes 
transcription factors, the proteins modulating expres-
sion of target genes at the transcription level. The latter 
includes proteins providing differential gene transcrip-
tion via the changing and maintenance of the chroma-
tin structure by a chemical modification of the DNA in 
promotor regions, particularly the 5′-methylation of 
cytosines in CpG islets, and methylation and acetyla-
tion of histones, amongst other modifications. Regula-
tion of gene transcription also involves the microRNAs 
(miRNAs) controlling gene expression at the posttran-
scriptional level [1].
Detached cell types, the so-called stem cells, are 
present at different stages of mammalian ontogenesis. 
These cells are characterized by a unique transcriptome 
and a complex of genetic and epigenetic components al-
lowing self-renewal; i.e., sustaining the stem status for 
a short or long time (depending on the stem cell type) 
and maintaining the capability of differentiation into 
various secondary cell types [2]. Stem cells may be sub-
divided into several subtypes, depending on how wide 
the daughter cell type spectrum is [2].
Totipotent cells can differentiate into all the possible 
cell types that a mature mammalian body consists of. 
These cells are also implicated in the formation of ex-
traembryonic tissues and organs, particularly placenta. 
In mammals, the only totipitent cells are the zygote and 
early cleavage stage blastomers.
Pluripotent cells can differentiate into descendants 
of all three germ layers: ectoderm, mesoderm, and en-
doderm. During ontogenesis, pluripotent cells can form 
a mature mammal body. However, they cannot produce 
extraembryonic tissues and organs. Pluripotent cells are 
in the inner cell mass and epiblast of mammal embry-
os, as well as their descendants, embryonic stem cells 
growing in vitro. Besides, embryonic germ cells that 
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originate from gamete precursors and epiblast stem 
cells isolated from postimplantation mouse embryos are 
also pluripotent [3–5]. In recent years, methods allow-
ing to make mature differentiated cells pluripotent by 
the introduction of exogenous factors have been devel-
oped. These cell types are called induced pluripotent 
stem cells (iPSCs). To date, iPSC lines of human, mouse, 
and some other mammals have been isolated [6–8].
Multipotent cells are region-specific stem cells (those 
of a mature body, which are located among differenti-
ated cells of various tissues) that can differentiate into 
several cell types. Examples of such cells are hemat-
opoietic stem cells differentiating into blood cells.
Unipotent cells are precursors of only one cell type. 
For instance, spermatogonial stem cells are precursors 
of male gametes.
As already mentioned, mammalian embryo blastom-
ers are totipotent up to an eight-cell stage. Each blas-
tomer of an 8-cell embryo possesses the potential to 
form all possible cell types, including the cells compris-
ing extraembryonic organs. This property of mamma-
lian blastomers was confirmed in experiments on the 
construction of aggregation chimeras. However, a tran-
sition to the 16-cell stage (morula) is associated with the 
first differentiation event. Each of the eight blastomers 
undergoes either a symmetrical division to form two 
polar outer cells of morula or an asymmetrical divi-
sion to form a polar outer cell and a nonpolar, relatively 
small, cell localized within the embryo. Thus, the fourth 
division of zygote produces an embryo composed of two 
first-specialized cell groups: the outer polar and the in-
ner nonpolar cells [9]. Following the next two-cell divi-
sions, the outer polar cells of morula form the outer cell 
layer called trophectoderm. It is required for the im-
plantation of the embryo into the uterine endometrium 
and formation of placenta. The trophectodermal cells 
form a sphere with the inner cavity, the blastocele. The 
inner nonpolar cells of the morula are transformed into 
the embryo inner cell mass (ICM) located at one end of 
the blastocyst on the inner side of the trophectodermal 
layer. Preceding implantation into the uterus, ICM is 
divided into two layers: the epiblast (primitive embry-
onic ectoderm) and the hypoblast (primitive embryonic 
endoderm). Throughout the course of its development, 
the epiblast gives rise to the embryo body (all tissues 
and organs), whereas the hypoblast forms the yolk sac. 
Thus, the mammalian preimplantation embryo (blasto-
cyst) is composed of three compartments: the trophec-
toderm, the hypoblast, and the epiblast, two of which 
(trophectoderm and hypoblast) produce extraembry-
onic tissues and organs and one that forms all the fetal 
tissues during further development [10]. The structure 
of preimplantation embryos is very similar in different 
mammalian species. The blastocysts of primates closely 
resemble those of rodents, featuring a greater number 
of cells and morphology after implantation. However, 
despite their similar structures, the blastocysts of pri-
mates differ from those of rodents in the time of com-
partmentation (into the trophectoderm, hypoblast, and 
epiblast) and are characterized by a longer preimplan-
tation development (7-10 days in primates compared 
with four days in mice) [11].
All three compartments of preimplantation em-
bryos (the epiblast, trophectoderm, and hypoblast) are 
sources of stable stem cell lines called embryonic stem 
cells, trophoblast stem cells, and extraembryonic stem 
cells, respectively. Cultured stem cells keep most of the 
features characteristic of their precursors, such as the 
gene expression pattern, epigenetic features, and many 
biochemical and physiological parameters. The stem 
status and correspondence of cell lines to their precur-
sors existing in vivo is best demonstrated by injecting 
the cells into a recipient blastocyst. After ESC injec-
tion, both TSC and extraembryonic ectodermal cells 
become involved in embryogenesis, contributing to the 
formation of the corresponding embryonic or extraem-
bryonic tissues and organs. All three cell types isolated 
from preimplantation embryos require specific culture 
conditions, such as the medium composition and pres-
ence of growth factors, in order to maintain their stem 
status. Sometimes, co-cultivation is necessary with 
other cell types synthesizing the factors required for 
maintenance of the undifferentiated state of stem cells 
[12–18].
Embryonic stem cells that possess self-renewal and 
pluripotency features are of particular interest. Self-
renewal implies the capability of infinite symmetrical 
division leading to the appearance of two pluripotent 
cells. As mentioned above, pluripotency is the capabil-
ity of a stem cell to differentiate into cell derivatives 
of all three germ layers, but not extraembryonic tis-
sues. Pluripotency is the characteristic that makes ESC 
a unique model for the investigation of the processes 
underlying cell differentiation and opens a broad ave-
nue for ESC use in fundamental research into biological 
events at early stages of mammalian ontogenesis, in-
cluding chromosome X inactivation, epigenetic genome 
changes, etc. Moreover, ESCs have practical use. Their 
unique features can be used in trials of novel drugs and 
studies of the toxicity of chemical substances. ESCs are 
a prominent source of biological material for cell re-
placement therapy in human diseases, although the is-
sue of how safe they are remains unsettled and under 
study.
At the moment, the focus of studies of ESC self-re-
newal and pluripotency is on their molecular basis. To 
date, it is known that a complex system of cell-surface 
proteins, their molecular signaling pathways, and the 32 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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transcription factors initiating or modulating target 
gene transcription sustain the pluripotency of pre-
implantation embryo cells and ESCs. Several signal-
ing cascades/pathways are implicated in maintaining 
pluripotency. These pathways constitute an external 
pluripotency regulation subsystem. A considerable 
body of experimental data suggests that this subsystem 
is not conservative. In particular, some signaling mol-
ecules, such as LIF and BMP4, have opposite effects on 
the self-renewal of mouse and human ESCs [19–21].
In addition to the subsystem of external regulators 
of pluripotency, there is a subsystem of internal regula-
tors which includes three transcription factors: OCT4, 
SOX2, and NANOG. These factors have a broad spec-
trum of target genes in murine and human ESCs, and 
their effect, unlike that of signaling pathways, is exclu-
sively directed toward maintaining self-renewal and 
pluripotency in various mammals [22, 23].
Recent data suggest a tight link between the two 
subsystems in ensuring a stable functioning of the en-
tire system that sustains self-renewal and pluripotency 
[24] (Fig. 1). The subsystems have also proved to inter-
act with proteins comprising the system of epigenetic 
regulation of gene expression (Polycomb and other pro-
teins) and with miRNAs specific for ESCs or various 
differentiated cell descendants.
SIGNALING CASCADES TRIGGERED BY INTERLEUKIN LIF
Initially, murine ESC lines were obtained using either 
mitotically inactivated fetal fibroblasts forming a feed-
er layer or a conditioned medium in which teratocarci-
noma cells or fetal fibroblasts were preliminarily grown 
for a given amount of time [12, 13]. Mouse ESC cultur-
ing without a feeder layer or in an unconditioned me-
dium resulted in cell differentiation. The nature of the 
agent secreted by fetal fibroblasts and required for sus-
taining the undifferentiated state of ESCs was deter-
mined later: the agent was interleukin LIF (Leukemia 
Inhibitory Factor), a member of the IL-6 family [25]. 
The recombinant LIF protein is currently widely used 
to isolate and culture mouse ESCs, in order to avoid the 
use of both a feeder and conditioned medium [26, 27]. 
The LIF protein, via interaction with a heterodimeric 
receptor LIFRβ-gp130 localized on the cell membrane, 
can activate three signaling cascades: JAK (tyrosine 
kinase Janus)-STAT3 (signal transducer and activa-
tor of transcription-3), the PI3K (phosphatidylinositol 
3-kinase)-mediated pathway, and the MAPK (mitogen-
activated protein kinase) cascade. Only JAK-STAT3 is 
activated solely by LIF, whereas the other two cascades 
are triggered by multiple molecular signals [24].
In the JAK-STAT3 cascade, LIF is the initial mo-
lecular signal that activates the transcription factor 
Fig. 1. System of “exter-
nal and internal regulators 
of pluripotency” in human 
ESC. Signal molecules 
and receptors on the cell 
plasmatic membrane are 
indicated by dark circles 
and blue rectangles, 
respectively. Gray, red, 
and green ovals indicate 
molecules involved in 
signal transmission from 
receptors to the cell’s 
nucleus and regulation of 
gene expression, togeth-
er with the transcription 
factors OCT4, SOX2, and 
NANOG in the cell’s nu-
cleus. Arrows represent 
activation and stoppers – 
repression as well and 
activity of SMAD1/5/8 
which induces hESC dif-
ferentiation.
cytoplasm
nucleus
regulation of gene expression
β-catenin
β-catenin
β-cateninREVIEWS
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STAT3. Its binding with the LIFRβ-gp130 receptor 
causes the activation of phosphoprotein kinases. Both 
the Janus tyrosine kinase and immunoreactive phos-
photyrosine kinase phosphorylate the tyrosine resi-
dues of the cytoplasmic part of the LIFRβ-gp130 het-
erodimer. The transcription factor STAT3 binds to the 
phosphotyrosine residues of the activated LIFRβ-gp130 
heterodimer and undergoes subsequent phosphoryla-
tion and dimerization. Phosphorylated STAT3 dimers 
are transported into the cell nucleus, where they inter-
act with the target genes [25, 28].
The important role of the LIF-STAT3 signaling 
pathway in sustaining the self-renewal of murine ESCs 
has been convincingly shown [29]. On the other hand, 
abundant data suggest a LIF-STAT3-independent 
mechanism sustaining ESC pluripotency in humans 
and other primates [21, 30].
Up until recently, not much data was available re-
garding the mechanisms of LIF implication in the 
maintenance of murine ESC pluripotency. Recent data 
provided by Niwa and colleagues [24] suggests the 
integration of LIF-triggered molecular cascades into 
the subsystem of internal regulators of pluripotency, 
whose components are the genes Oct4, Sox2, and Na-
nog (Fig. 1). This integration takes place via two path-
ways: JAK-STAT3 and PI3K-mediated. STAT3 acti-
vates the expression of KLF4 (Krüppel-like factor 4), 
which, in turn, is a positive regulator of the Sox2 gene. 
In parallel, the PI3K signaling cascade activates a gene 
encoding another transcription factor, TBX3, which 
then activates the Nanog gene. Moreover, inhibitors of 
MAPK that mediate the third, LIF-activated signaling 
cascade cause the accumulation of the TBX protein in 
the cell’s nucleus and the activation of the Tbx3 and 
Nanog genes (Fig. 2). Moreover, LIF can indirectly (via 
MAPK) activate TBX3 transport (Fig. 2), but this path-
way seems to be inhibited by some third factor.
TGFβ/ACTIVIN/NODAL, BMP, AND BFGF 
(FGF2) SIGNALING PATHWAYS
The TGFβ (transforming growth factor-β) superfamily 
includes a large number of signaling molecules (about 
40 putative protein ligands of TGFβ are found in hu-
mans). This superfamily may be subdivided into two 
large groups of activators:
1) TGFβ/ACTIVIN/NODAL activating the tran-
scription of SMAD2/3 (similar to mothers against de-
capentaplegic homologue) transcription factor genes 
via receptors of ALK4 (activin-like kinase 4), ALK5, 
and ALK7;
2) BMP (bone morphogenic protein)/GDF (growth 
differentiation factor) activating SMAD1/5 via the re-
ceptors of ALK1, ALK2, ALK3, and ALK6. Also, two 
proteins of the SMAD family are inhibitors of the same 
family members: SMAD6 selectively inhibiting the 
SMAD1/5 and SMAD7 suppressing protein activators 
in both branches of the TGFβ superfamily [31].
The TGFβ/ACTIVIN/NODAL signaling pathway 
plays an essential role in sustaining human ESC (hESC) 
pluripotency. The ACTIVIN and NODAL proteins act 
via the same receptors to suppress hESC differentia-
tion [32–34]. Human ESCs express both the ACVR1B 
and ACVR1B receptors and the TDGF1 (CRYPTO) 
coreceptor of NODAL, as well as NODAL itself [35]. In 
hESC cultures, NODAL and ACTIVIN can act in con-
cert with other protein factors, such as bFGF (FGF2) 
and WNT, in the maintenance of hESC self-renewal 
[32, 34, 36, 37]. ACTIVIN can activate the production 
of bFGF, which is necessary for sustaining the self-re-
newal of hESC cells cultured in the absence of a serum 
[36]. Both ACTIVIN and NODAL can be replaced with 
TGFβ in hESC cultures.
The protein factor NODAL plays many different 
roles during the early embryogenesis of mice. It is nec-
essary for the normal development of embryo epiblast 
and the maintenance of human  OCT4 and NANOG 
gene expression. A high level of activity of NODAL/
Fig. 2. Interplay between transcription factors and LIF-
mediated signaling pathways in mouse embryonic stem 
cells [24].
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ACTIVIN/TGFβ directed toward the activation of 
SMAD2/3B transcription factors (Fig. 1) is observed 
in undifferentiated hESCs. The transcription factors 
SMAD2 and SMAD3 are implicated in NANOG tran-
scription activation. Undifferentiated hESCs exhibit a 
high level of phosphorylated (active) forms of SMAD2 
and SMAD3. Inhibition of SMAD2/3 phosphorylation 
by specific inhibitors results in a lowered OCT4 and 
NANOG gene expression level [32]. During differentia-
tion, the activity of SMAD2 and SMAD3 decreases with 
an increase in the level of SMAD1/5/8 activating BMP 
(Fig. 1). SMAD1/5/8 proteins suppress NANOG gene 
transcription. Moreover, SMAD2 and SMAD3, as well 
as the signaling pathway triggered by FGF2 (bFGF), 
inhibit the expression of BMP4, thus blocking the spon-
taneous differentiation of hESCs [37].
The GDF protein, a member of the TGFβ super-
family, not only inhibits BMP, but also potentiates the 
effect of NODAL (Fig. 1). The GDF gene is expressed in 
pluripotent cells of humans and mice, through implica-
tion in the suppression of the BMP-mediated differen-
tiation. Eventually, GDF influences ESC self-renewal 
by establishing a balance between SMAD2/3 and 
SMAD1/5/8 [38, 39] (Fig. 1).
The protein factors of the BMP group have the oppo-
site effect on the self-renewal of murine ESCs (mESCs). 
BMP4 suppresses neural differentiation and, taken in 
combination with LIF, sustains the symmetrical self-
renewal of mESCs in the absence of both the feeder 
layer and serum. Murine BMP4 activates the expres-
sion of the transcription factor SMAD4 that, in turn, 
activates the transcription of genes belonging to the 
Id (inhibitor of differentiation) family. It is likely that 
the expression of the Id1, Id2, and Id3 genes in ESCs 
suppresses the effects of the early expression of genes 
encoding proneuronal transcription factors (bHLH), 
particularly Mash members, thus preventing differ-
entiation [40]. However, BMP4 in the absence of LIF 
can have an opposite activating effect on SMAD family 
factors (SMAD1/5/8), which inhibit the expression of 
Id family genes [40].
Thus, the signaling pathways and cascades triggered 
by BMP and LIF-JAK-STAT3 have opposite effects on 
hESC and mESC self-renewal. This is not a solitary ex-
ample of the species-specific effect of signal molecules. 
For instance, bFGF is critical in sustaining the undif-
ferentiated state of hESC, but it causes the differentia-
tion of mESCs [41, 42]. Human ESCs express both the 
receptor and bFGF itself [43, 44]. The effect of bFGF 
is mediated by tyrosine kinase receptors (ERK1 and 
ERK2), and inhibition of this signaling pathway results 
in hESC differentiation (Fig. 1). It is worth noting, how-
ever, that the mechanism of bFGF action on hESCs has 
yet to be understood in detail.
WNT SIGNALING PATHWAY
Recent studies show that the signaling pathway, of 
which WNT is a key element, is involved in the short-
term maintenance of the pluripotent state of both 
mESCs and hESCs [45]. The inhibition of glycogen syn-
thase kinase 3 (GSK-3) results in the activation of the 
WNT signaling pathway and leads to the accumula-
tion of β-catenin in the cells’ nuclei and the activation 
of a series of target genes. However, the expression of 
the Oct4, Rex1, and Nanog genes, which is specific to 
pluripotent cells, is retained even in the absence of LIF 
[46] (Fig. 1). Nevertheless, it was shown later that re-
taining hESC self-renewal for longer requires TGFβ 
and bFGF, and that the action of WNT is restricted to 
intensifying proliferation [47, 48].
TRANSCRIPTION FACTORS OCT4, NANOG, AND SOX2
The transcription factors OCT4, NANOG, and SOX2 
play a central role in the subsystem of internal regula-
tors of pluripotency. Unlike a system of species-spe-
cific signaling pathways, the functions of these tran-
scription factors essentially intersect in sustaining the 
pluripotency of hESCs and mESCs. Both the genomic 
organization of the Oct4, Sox2, and Nanog genes and 
the domain structure of the OCT4, NANOG, and SOX2 
proteins are conserved, and the spectra of the target 
genes of these factors are similar in mESCs and hESCs. 
Both in mice and humans, OCT4, NANOG, and SOX2 
act collectively to form an integrated system regulat-
ing gene transcription, including the autoregulation of 
their own genes.
TRANSCRIPTION FACTOR OCT4
The OCT4 protein is a POU (Pit, Oct, Unc) class V fam-
ily of transcription factors. The POU-domain is a bi-
partite domain composed of two subunits separated 
by a nonconserved region whose length varies. The N-
terminal subunit (75 aa) is known as the POU-specific 
(POUs) domain, while the C-terminal subunit (60 aa) is 
a homeobox domain [49–51]. OCT4 expression is char-
acteristic of early embryogenesis in humans, mice, and 
other mammals [52–56]. In mice, its expression is traced 
above the two-cell stage and is restricted to the pluripo-
tent cells of ICM and epiblast. In postimplantation em-
bryos, OCT4 is only expressed in germ cells. In human 
blastocyst, OCT4 is found not only in ICM, but also in 
the trophoblast [57]. The role of OCT4 in embryogenesis 
was demonstrated in experiments with Oct4 knock-
out mice (the gene Oct4 is also known as Pou5f1, Oct3, 
Oct3/4, OTF3, and OTF4). Homozygous (Oct4-/-) mouse 
embryos died at the stage of implantation due to their 
inability to form ICM (composed of pluripotent cells), 
while the development of trophoblast was normal [53]. 
Later, Niwa and colleagues demonstrated the effect of REVIEWS
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the Oct4 expression level on mESC self-renewal [58]. A 
variation in the Oct4 transcription level by 50% results 
in the differentiation of mESCs into either trophoblas-
tic or endodermal derivatives [58]. Moreover, OCT4 ac-
tivity is necessary for the normal life of murine germ 
cells [59]. Inhibition of Oct4 gene expression in murine 
and human ESCs by means of RNA-interference also 
results in their differentiation into different derivatives 
expressing trophoblastic and endodermal markers, 
such as Cdx2, Gata6, and AFP [60, 61]. Studies of the 
Oct4 genomic structure, the structure of the regulatory 
region, and chromosomal localization in humans and 
other mammals have shown a highly conserved mo-
lecular organization of this gene. Besides, it was shown 
that in a series of mammal species the Oct4 gene maps 
onto a similar syntenic group [62–65]. In mice and other 
animals, Oct4 is composed of five exons and localized 
in the main histocompatibility complex (MHC) region 
[62, 63, 65, 66]. The human OCT4 gene is also localized 
within the MHC region; however, three variants of 
its alternative splicing, OCT4A, OCT4B, and OCT4B1, 
were demonstrated [62, 67]. The proteins encoded by 
these isoforms are involved to different levels in the 
maintenance of pluripotency. OCT4B, which is largely 
localized in the cytoplasm, cannot sustain the pluripo-
tency of ESCs [68]. In humans, OCT4A is expressed at 
the stage of compact morula and blastocyst, whereas 
OCT4B is expressed in all embryonic cells above the 
four-cell stage. Moreover, OCT4B is not expressed in 
hESCs [69]. Unlike the Oct4 of other animals, human 
OCT4 has four exons. The second exon is subdivided 
into four subexons (2a, 2b, 2c, and 2d) that differently 
combine with each other in three different variants of 
transcript splicing. The variant OCT4A is composed of 
exons 1, 2b, 2d, 3, and 4; OCT4B – 2a, 2b, 2d, 3, and 4; 
OCT4B1 – 2a, 2b, 2c, 3, and 4. Thus, the human OCT4 
gene transcripts are identical in 3’-area (exons 3 and 
4), and the difference only concerns exons 1 and 2. The 
OCT4A transcript encodes a protein with a length of 
360 aa. The size of OCT4B is 265 aa; however, in some 
parts of the population this protein type is not trans-
lated because of the polymorphism of its start codon 
(AU/GG) [62, 70]. Another two isoforms, OCT4B-190 
and OCT4B-164 composed of 190 and 164 aminoacid 
residues, respectively, can be translated from the re-
cently found alternative ribosome-binding site local-
ized in the area of the OCT4B transcript subexons 2a-b. 
The protein product of OCT4B1 was not found, maybe 
because of the UGA stop codon in the subexon 2c that 
is absent in OCT4B [67]. It was shown earlier that the 
protein encoded by the OCT4A isoform is localized in 
the cell nucleus and involved in the regulation of gene 
transcription, while the OCT4B protein is localized in 
the cytoplasm and cannot maintain pluripotency [57, 
68]. Later, it was found that both  OCT4B products, 
OCT4B-190 and OCT4B-164, are dispersed in both 
the nucleus and cytoplasm [70]. In hESCs, the level of 
OCT4B-190 considerably increases in response to stress 
conditions and can inhibit apoptosis. No expression of 
OCT4B-265 and OCT4B-164 was found in hESCs [70].
TRANSCRIPTION FACTOR NANOG
The transcription factor NANOG is a homeodomain 
protein that shares a very high degree of homology and 
structural resemblance with NK family proteins [71]. 
The expression of the NANOG gene is characteristic of 
preimplantation embryo pluripotent cells (ICM and epi-
blast), as well as murine and human ESCs [72–74]. Na-
nog overexpression can lead to the retention of mESC 
pluripotency, even in the absence of interleukin LIF 
[72]. The mutation analysis of Nanog has shown how 
necessary this gene expression is for normal embryonic 
epiblast development and maintenance of mESC self-
renewal. ESCs with the genotype Nanog-/- differentiate 
into extraembryonic derivatives [73]. Suppression of 
NANOG expression in hESCs results in differentiation 
accompanied by elevated expression of endodermal 
(GATA4, GATA6, LAMININ B1, and AFP) and trophec-
todermal (CDX2, GATA2, hCG-α, and hCG-β) markers.
The murine NANOG molecule in mice has several 
functional elements involved in transactivation. These 
include the homeodomain, which occupies a central po-
sition in the protein, and three C-terminal elements: 
CD1 (C-terminal domain 1), CD2, and the tryptophan 
repeat (W-repeat) localized between CD1 and CD2. 
Homeodomain, CD2, and the W-repeat chiefly con-
tribute to the transactivation of murine NANOG [75, 
76]. Recent studies have shown that the murine NA-
NOG W-repeat provides transactivation; it is involved 
in NANOG protein dimerization that is necessary for 
LIF-independent maintenance of mESC pluripotency 
[77, 78]. In all likelihood, tryptophan residues are the 
most essential. Their replacement by alanines results 
in a substantial decrease in the murine NANOG trans-
activation capability, whereas the replacement of any 
other aminoacid residue in the W-repeat monomer has 
no significant effect on this activity [76]. Another im-
portant transactivation element of NANOG is CD2 [79]. 
This element is required for the  NANOG-mediated 
self-renewal of mESCs. CD2 domain activity depends 
on aromatic residues (phenylalanine and tyrosine). Re-
placement of these aminoacids leads to a decrease in the 
CD2 and entire NANOG activity and, as a result, leads 
to ESC differentiation [79]. Nevertheless, a compari-
son of different mammalian CD2 sequences has shown 
that the majority of aromatic aminoacid residues are 
not conserved to a high level [80].36 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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TRANSCRIPTION FACTOR SOX2
Transcription factor SOX2 (SRY-related HMG box) 
contains the DNA-binding HMG (high mobility group)-
domain. Expression of SOX2, as well as OCT4, is char-
acteristic of the ICM, epiblast, and germ cells of mice 
embryos [81].
Homozygous SOX2 mutant embryos die at the stage 
of implantation because of the epiblast hypoplasia. It 
is impossible to obtain stable ESC lines from mutant 
embryos, but both TSC and extraembryonic endoder-
mal lines are easily prepared [81]. In addition, a normal 
expression of Sox2 gene is necessary for sustaining the 
self-renewal of murine and human ESCs [82, 83]. Both 
suppression and overexpression of SOX2 cause troph-
ectodermal differentiation of hESCs [83].
GENE TARGETS FOR OCT4, NANOG, AND 
SOX2 TRANSCRIPTION FACTORS
OCT4, NANOG, and SOX2 are the proteins whose ex-
pression is necessary for sustaining murine and human 
ESC pluripotency under standard culturing conditions. 
It is evident that their function as transcription factors 
determines general ESC features. At present, much 
data exist concerning the spectrum of target genes for 
these proteins.
The transcription factor OCT4 can serve as the ac-
tivator and repressor of many target genes, such as 
Fgf4, Opn, Utf1, and the genes encoding human cho-
rionic gonadotropin α- and β-subunits, most of them 
participating, in one way or another, in early embryo 
development [84–88]. The regulatory forms of OCT4 
are mono-, homo-, and heterodimer, depending on the 
target gene [89]. For instance, the OCT4 homodimer 
regulates the transcription of Opn. The enhancer el-
ement of Opn contains a palindromic sequence called 
PORE (palindromic-oct-regulatory-element), which 
contains the octameric ATGCAAAT motif (octamer-
ic site for the docking of the OCT monomer) and the 
ATTTG sequence separated from the octameric motif 
by two nucleotides. The SOX2 docking site is localized 
near PORE; however, it exerts a suppressing effect on 
Opn transcription [84].
The OCT4 and SOX2 factors can act in conjunction. 
They positively regulate Fgf4 and Utf1 genes, and their 
docking sites are localized in the enhancers localized in 
the 3′-nontranslated regions of these genes [85, 86, 90]. 
Aside from PORE, another element exists which in-
teracts with OCT monomers and dimers; it was named 
MORE (more of PORE,  ATGCATATGCAT) [91, 92]. 
MORE and PORE elements are substantially different 
in the relative localization of the POU-specific domain 
and POU-homeodomain. Despite an initially artificial 
synthesis of MORE, similar elements were found in the 
regulatory regions of natural genes [91–93]. OCT1 and 
OCT4 transcription factors can influence the target 
gene’s transcription via MORE elements in response to 
genotoxic and oxidative stresses [93].
The development of high-performance methods for 
the distribution analysis of transcription factors at the 
whole genome level has substantially broadened our 
knowledge of the spectrum of OCT4, NANOG, and 
SOX2 target genes. Two research groups have localized 
OCT4, NANOG, and SOX2 in the human and mouse 
ESC genomes using ChIP-on-Chip and ChIP-PET 
(chromatin immunoprecipitation – pared-end ditag) 
methods [22, 23].
The distribution of binding sites for the OCT4, NA-
NOG, and SOX2 transcription factors in human H9 
ESCs was analyzed by Boyer and colleagues [22]. The 
genes encoding transcription factors and the compo-
nents of signaling pathways which, as determined 
earlier, are implicated in early embryogenesis, cell dif-
ferentiation, organogenesis, and maintenance of ESC’s 
self-renewal and pluripotency in culture are a major 
part among the genes associated with these transcrip-
tion factors. Particularly, they are OCT4, SOX2, NA-
NOG, LEFTY2/EBAF, CDX2, HAND1, DPPA4, GJA1/
CONNEXIN43, FOXO1A, CRIPTO/TDGF1, and ZIC3 
[94–102]. Then, the distribution of binding sites for 
the NANOG and SOX2 factors was determined in the 
same way. The OCT4, SOX2, and NANOG transcrip-
tion factors jointly regulate 353 genes in hESCs; they 
can act as transcription activators or repressors [22]. 
The transcription factor genes, such as OCT4, NANOG, 
and SOX2, as well as genes encoding components of 
the signaling pathways implicated in the sustenance of 
self-renewal, such as TGFβ (TDGF1, LEFTY2/EBAF) 
and WNT (DKK1, FRAT2), make up a large portion 
of the genes positively regulated by OCT4, NANOG, 
and SOX2 [22]. Also, transcription factor genes, such 
as Rcor2, Esrrb, and Phc1, were revealed in mESCs 
among the genes positively regulated by the OCT4 and 
NANOG factors [23]. In addition, Pou5f1 (encoding the 
OCT4 transcription factor) and Sox2 are on the list of 
the genes positively regulated by NANOG in mESCs. 
Early experimental data also suggest the involvement 
of the OCT4 and SOX2 factors in the regulation of the 
Pou5f1, Sox2, and Nanog genes [97, 99, 100, 103]. It ap-
pears that autoregulation is the general property of the 
system maintaining pluripotency in mice and humans. 
The abundance of genes encoding transcription factors 
(such as REST, SKIL, HESX1, and STAT3) among the 
positively regulated genes suggests that OCT4, NA-
NOG, and SOX2 are only the tip of an iceberg, hiding 
a far more complex system of transcription regulation 
in ESCs. Many genes encoding the transcription factors 
(for instance, ESX1I, HOXB1, MEIS1, PAX6, LHX5, 
LBX1, MYF5, ONECUT1) involved in differentiation REVIEWS
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during embryo development are found among the neg-
atively regulated genes [22]. It is very likely that the 
OCT4, NANOG, and SOX2 factors participate in the 
repression of these genes both in vivo and in vitro.
Data published in two studies seem to indicate that 
the binding sites for the OCT4, NANOG, and SOX2 
transcription factors are associated with the genes en-
coding miRNAs [22, 23]. In hESCs, the docking sites for 
OCT4, NANOG, and SOX2 are found in the promotors 
of 14 miRNA genes; they are all present in the mir-137 
and mir-301 promotors. In mESCs, the binding sites for 
NANOG are localized within a distance of 6 kbp from 
four miRNA genes: mir-296, mir-302, mir-124a, and 
mir-9-2. Moreover, no other genes are found in close 
vicinity to the NANOG site in the case of the mir-296, 
mir-124a, and mir-9-2 genes. The docking site for NA-
NOG is found within a 30-kbp region for the mir-135 
gene, while OCT4 binds in close vicinity to the NANOG 
site near the mir-296 and mir-302 genes.
A comparison of data on the revelation of target 
genes for the OCT4 and NANOG transcription factors 
in mouse and human ESCs demonstrates that only a 
minor portion of these genes are simultaneously found 
in the genomes of both species. So, only 9.1% OCT4-
associated genes and 13% NANOG-associated genes 
overlap in these two species. This may be evidence of 
an essential difference in the composition of the gene 
nets controlled by OCT4 and NANOG. However, a 
group of 32 genes is regulated by OCT4 and NANOG 
in both mouse and human, 18 of them encoding tran-
scription factors, including OCT4, SOX2, and NANOG, 
suggesting the importance of these genes in sustaining 
pluripotency [23]. The difference in the compositions of 
the target genes found in these two studies may have 
a technical origin, because two different methods were 
employed in the works (ChIP-on-Chip and ChIP-PET, 
respectively) to obtain data and process them.
Thus, the OCT4, NANOG, and SOX2 transcription 
factors are in the center of a broad regulatory net in-
cluding transcription factors (whose genes are posi-
tively or negatively regulated), components of signaling 
pathways, and miRNAs. The stable functioning of this 
net is evidently necessary for sustaining self-renewal 
and pluripotency in both human and murine ESCs.
PROTEIN-PROTEIN INTERACTIONS IN THE PLURIPOTENCY 
MAINTENANCE SYSTEM IN EMBRYONIC STEM CELLS
Recent studies provide much evidence pointing to the 
fact that the transcription factors involved in the main-
tenance of ESC self-renewal not only exert joint control 
on target gene transcription, but they are also in physi-
cal contact with each other [104–108]. For instance, 
NANOG can suppress BMP-initiated mesodermal dif-
ferentiation in mESCs via binding with SMAD1 and 
physically interact with the SALL4 transcription factor 
to execute joint positive regulation of the Nanog and 
Sall4 gene enhancers [104, 106]. However, these were 
only particular examples of protein-protein interac-
tions of NANOG directed toward the maintenance of 
ESC self-renewal. A wider analysis of NANOG inter-
actions on mESCs has demonstrated a broad spectrum 
of interactions. The set of interacting proteins includes 
not only transcription factors, but also the proteins im-
plicated in chromatin structure regulation [105]. Wang 
and colleagues [105] applied a method based on the 
expression of the NANOG protein containing FLAG-
epitope and a short amino acid sequence serving as the 
substrate for BirA, the Escherichia coli biotin ligase. 
A NANOG containing two additional epitopes was ex-
pressed (at the level of about 20% of the endogenous 
level) in mESCs that also expressed BirA, and the cells 
retained self-renewal and pluripotency. NANOG com-
plexes were isolated from the nuclei extract either by 
using streptavidin-agarose or by immunoprecipitation 
with antibodies against FLAG, followed by purifica-
tion on streptavidin-agarose. The proteins interacting 
with NANOG were identified using mass-spectrome-
try (whole-lane liquid chromatography–tandem mass 
spectrometry, LC–MS/MS).
Several regularities can be detected from the data 
obtained in this experiment. In the first, the group of 
proteins interacting with NANOG is much enriched in 
the factors required for the normal viability and dif-
ferentiation of ICM cells (pluripotent embryo compart-
ment) in mouse blastocyst. Besides, according to data in 
the literature, more than 80% of NANOG-interacting 
proteins, such as OCT4, DAX1, NAC1, ZFP281, and 
SALL4, are required for the acquisition and mainte-
nance of general ESC properties [105].
Secondly, most of the revealed proteins possess a 
similar expression pattern, which is typical of pluripo-
tent cells, and their expression is suppressed under ESC 
differentiation, likely suggesting their involvement 
in similar processes or in the same regulatory system 
[105].
Thirdly, in human and murine ESCs a large portion 
of genes encoding the proteins interacting with NA-
NOG represents putative targets for OCT4 and NA-
NOG [22, 23, 63]. The system sustaining ESC self-re-
newal and pluripotency in mice and humans undergoes 
autoregulation with positive and negative feedbacks, 
a feature that is necessary for both the stability of the 
undifferentiated state and the realization of a strict dif-
ferentiation program in a distinct direction [97, 99, 100, 
103]. It is likely that the maintenance of pluripotency or 
direction of cell differentiation depends on the stoichio-
metric ratio between the molecules of different factors. 
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ESC multidirectional differentiation depending on the 
transcription levels of the Oct4, Nanog, and Sox2 genes 
[58, 83, 109].
Fourthly, NANOG can interact via its partners with 
multiple proteins involved in the epigenetic regula-
tion of gene expression. NANOG – via interaction with 
OCT4, DAX1, NAC1, ZFP281, or SALL1/4 – can form 
complexes with components of the NuRD complex 
(P66B and HDAC2) possessing histone acetylase activ-
ity, Polycomb proteins (YY1, RNF2, and RYBP), and 
components of the SWI/SNF (BAF155) chromatin re-
modeling complex [105]. The interaction of NAC1 and 
SALL1 with histone deacetylases has been experimen-
tally proved [110, 111].
Complexes formed by NANOG and other proteins 
are apparently functional, rather than occasional short-
live intermediates observed in a single experiment. For 
instance, the complex formed by NAC1, ZFP281, and 
NANOG interacts with the Gata6 promoter (the mark-
er of endodermal differentiation) to inhibit it.
Interaction between OCT4 and other protein mol-
ecules was also reported in a series of works [85, 
112–114]. Particularly, these are interactions between 
OCT4 and transcription factors with the formation of 
heterodimers that are necessary for regulating target 
gene transcription. In addition, proteins interacting 
with OCT4 and inhibiting this factor were found using 
the yeast two-hybrid system and co-immune precipita-
tion [115]. SUMO-ligase PIASy, as well as PIAS1, and 
PIAS3 proteins belonging to the same family interact 
with OCT4. Despite PIASy being a known SUMO-ligase 
and the OCT4 protein containing sumoylation sites, 
the inhibitory effect of the ligase was experimentally 
proved to be independent of this activity. PIASy exerts 
the inhibitory effect on the transactivating capability 
of OCT4, acting as a monomer, homo-, or heterodimer, 
whereas PIAS1 and PIAS3 do not exhibit this action. 
Also, the PIASy, PIAS1, and PIAS3 proteins induce 
the relocation of OCT4, pushing it to the nucleus’s pe-
riphery [115].
Two research groups recently carried out a study 
on the patterns of protein-protein interactions of the 
OCT4 factor, as well as its known partners:  SALL4, 
TCFCP2L1, DAX1, and ESRRB in mESCs [107, 108]. 
The authors employed an approach based on the ex-
pression of a chimeric protein (OCT4 in this case) con-
taining known epitopes, which are necessary for the 
isolation of its complexes with other proteins from cel-
lular or nuclear extracts. Expression of Oct4 under its 
natural promotor was used in one of these works [107]. 
Like in the work by Wang and colleagues [105], com-
ponents of the NuRD, SWI/SNF, and PRC1 complex-
es involved in the regulation of the chromatin struc-
ture were found among the proteins interacting with 
OCT4 [107, 108]. Also, some enzymes participating in 
the epigenetic regulation of gene expression, such as 
MYST2 (histone acetyltransferase H4), DNMT3A (de 
novo DNA-methyltransferase), and some other pro-
teins, were found in OCT4 complexes. Some proteins 
involved in the posttranslational modification of OCT4 
itself, particularly OTG (enzyme attaching O-bound 
N-acetyl glucosamine), modifying OCT4 in hESCs were 
also found [107, 108, 116]. The transcription factors nec-
essary for the maintenance of ESC self-renewal, such 
as KLF4, SOX2, SALL4, and ZFP281, are found among 
the partners of OCT4. Analysis of the functions of OCT4 
partners using information from databases has shown 
that they are mostly involved in early development 
and cell differentiation and that their knockout induc-
es death during the early development of the embryo 
[107]. All genes determined as OCT4 partners in mESCs 
have human homologues. Moreover, the aminoacid se-
quences of the proteins encoded by these genes show 
a very high, more than 94%, homology between mice 
and humans (the average level is 77%). These genes are 
closely associated with the development of inherited 
diseases in humans (mostly with developmental disor-
ders) and cancer [107].
Thus, gene regulation directed toward the mainte-
nance of self-renewal and pluripotency appears more 
complex than was earlier thought. Not just the sup-
pression or activation of target genes by distinct protein 
molecules of the transcription factors is involved in the 
regulation. There are molecular complexes implicated 
in the regulation which contain not only transcription 
factors, but also proteins remodeling the chromatin 
structure. The quantitative ratio of the molecules in 
each separate cell can directly or indirectly influence 
its self-renewal and direction of differentiation.
EPIGENETIC REGULATION OF CELL PLURIPOTENCY
ESCs possess a virtually unlimited potential for self-
renewal and differentiation into a very broad spectrum 
of cell types. Global changes in morphology, physiol-
ogy, division rate, and other parameters occur dur-
ing cell differentiation. These changes are caused and 
accompanied by a global change in the gene expres-
sion pattern. Currently, gene expression is known as a 
process that is strictly regulated at the epigenetic level. 
Epigenetic regulation includes covalent modification 
of histones (nucleosome-forming proteins) and DNA 
methylation in gene promotor regions. Numerous types 
of histone modifications, such as acetylation, methyla-
tion, phosphorylation, ubiquitinylation, etc., are known, 
consisting in the attachment of chemical groups and 
regulatory peptides (ubiquitin, SUMO) to the aminoac-
id residues of histones. Histone modifications alter the 
physical properties of nucleosomes, thus making chro-REVIEWS
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matin more or less accessible to the factors providing 
gene transcription. The modifications associated with 
active chromatin and actively transcribed genes and, 
alternatively, the modifications associated with inac-
tive chromatin and often associated with transcription 
suppression have been distinguished. In particular, the 
acetylated forms of the histones H3 and H4 and his-
tone H3 trimethylated at position K4 (H3K4me3) (K 
is lysine, according to the single-letter nomenclature) 
are “active” modifications. Alternatively, histone H3 
di- and trimethylation at position K9 (H3K9me2 and 
H3K9me3) and histone H3 di- and trimethylation at po-
sition K27 (H3K27me2 and H3K27me3) are “inactive” 
chromatin modifications. Moreover, inactive chromatin 
is characterized by histone deacetylation.
In mammals, DNA methylation touches cytosines 
within the CpG-dinucleotide islets. These islets are 
often observed in promotor regions, and their hyper-
methylation is commonly associated with transcription 
suppression.
Studies on the localization of modified histones in the 
genomes of embryonic stem cells demonstrate that the 
distribution of active and inactive modifications is rath-
er unusual and specific to pluripotent cells. The pres-
ence of bivalent domains simultaneously containing the 
labels of active and inactive chromatin (H3K4me3 and 
H3K27me3) was discovered in the mESC genome [117]. 
A distribution analysis of histone H3 active and inac-
tive modifications has been carried out for 56 regions 
enriched with highly conserved noncoding element 
(HCNE) sequences. HCNE-enriched regions generally 
not contain many genes: however, they do encompass 
a relatively large number of genes encoding the tran-
scriptional factors implicated in the regulation of devel-
opment. For instance, all four clusters of the HOX gene 
family are localized in these regions. Within HCNE, 
Bernstein and colleagues [117] have demonstrated the 
presence of 343 H3K4me3-enriched regions averaging 
3.4 kb; 63% of them are co-localized with the transcrip-
tion initiation points of known genes. In addition to this, 
192 regions enriched with H3K27me3 were found with-
in HCNE sequences with a maximum length of 18 kb in 
the gene clusters of the HOX family. A comparison of 
data on the H3K4me3 and H3K27me3 distributions has 
revealed domains containing both modifications. Nine 
similar domains were found in HOX clusters; 95, in oth-
er HCNE-enriched regions; whereas only five bivalent 
domains were identified in control loci [117].
Most bivalent domains in HCNE-enriched regions 
are associated with the transcription initiation points of 
the genes encoding transcription factors. These genes 
are members of the SOX, FOX, PAX, IRX, and POU 
families, whose distinct members play important roles 
in cell differentiation during development. However, 26 
bivalent domains were found beyond the transcription 
initiation points; they are also associated with the genes 
implicated in development. For instance, bivalent do-
mains are found in the 3′-regions of the Npas3, Meis2, 
Pax2, and Wnt8b genes. Bivalent domains are present 
in the Fgf8 and Prok1 genes that do not encode tran-
scription factors but participate in the development of 
the nervous system [117].
An extremely small number of bivalent domains 
were found in the differentiated cells studied by the 
authors, such as embryonic fibroblasts, primary lung 
fibroblasts, C2C12 myoblasts and Neuro2a neuroblas-
toma cells. At the same time, extended regions enriched 
separately with H3K4me3 or H3K27me3 were found. In 
differentiated cells, the overwhelming majority of the 
domains among the bivalent ones revealed in mESCs 
contained extended regions represented by only one 
modification, depending on cell type [117].
The genes, whose transcription start points are as-
sociated with bivalent domains, are characterized 
by a low transcription level, despite the presence of 
H3K4me3, the active chromatin label, thus suggesting 
a “predomination” of H3K27me3 over H3K4me3. The 
authors studied the distribution of the modifications in 
the bivalent domains associated with gene transcrip-
tion start points during a directed ESC differentia-
tion into neural cell progenitors. The genes with a high 
transcription level after the differentiation lost the 
H3K27me3 modification, while the genes transcribed 
at a low level enhanced enrichment in H3K4me3, in 
line with the preservation of H3K27me3, and nontran-
scribed genes preserved H3K27me3 and lost H3K4me3 
[117].
Thus, a specific system of epigenetic gene regula-
tion exists in the ESCs involved in cell differentiation. 
Apparently, it enables pluripotent cells to keep distinct 
genes in the “low start” state and rapidly start their 
transcription depending on differentiation programs 
and type of the formed differentiated cells.
The molecular mechanisms underlying the epige-
netic regulation of gene expression in ESCs are being 
studied in detail. Polycomb group proteins are one of 
the main actors in the epigenetic regulatory system 
in embryo development in organisms and ESCs [118]. 
Numerous biochemical and genetic studies show that 
Polycomb proteins form two independent complexes: 
PRC1 (Polycomb repressive complex 1) and PRC2. The 
main components of these complexes are highly evo-
lutionarily conserved and necessary for a normal em-
bryonic development of various organisms, from dro-
sophila to mouse and humans [118–122].
Boyer and colleagues have analyzed the localization 
of the main components of PRC1 (PHC1, RNF2) and 
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ing the transcription start points (from –8 to +1 kb) of 
about 16,000 genes in mESCs [123]. The authors have 
found that PRC1 and PRC2 proteins are mostly localized 
within 1 kb of the transcription start point of 512 genes, 
thus suggesting their involvement in the regulation of 
these genes. Earlier, PRC2 was shown to be responsible 
for the establishment of H3K27me3, the label of inactive 
chromatin. The study has demonstrated that H3K27me3 
enrichment takes place in all 512 genes whose 5′-regions 
can carry PRC1 and PRC2 proteins. The genes encoding 
homeodomain-containing transcription factors represent 
a significant portion of them. Previously known targets 
of Polycomb proteins – factors of the HOX family and 
other transcription factors belonging to DLX, IRX, LHX, 
POU, PAX and SIX families – belong to this group. A 
common feature of the factors belonging to these fami-
lies is their implication in cell differentiation and regula-
tion in embryo development and organogenesis. Genes 
whose products are implicated in the regulation of de-
velopment despite the absence of a homeodomain were 
also revealed. These are proteins of FOX, SOX, GATA, 
and TBX families. In cells bearing homozygous EED mu-
tation (one of the PRC2 components), a high expression 
level of genes belonging to various families is observed, 
although these genes are silenced in normal ESCs [123].
Thus, multiple genes implicated in differentiation 
and embryo development in mESCs are targets for PRC. 
Hence, PRC1 and PRC2 can play a substantial role in the 
maintenance of ESC self-renewal and pluripotency.
Similar results were obtained in a study on the lo-
calization of the SUZ12 protein (another PRC2 com-
ponent) in hESCs [124]. The authors also succeeded 
in proving that PRC2 components are localized in the 
vicinity of the transcription start points of the genes 
implicated in many processes associated with cell dif-
ferentiation during embryo development. Besides, in 
hESCs the SUZ12 protein is localized in the promoters 
of genes encoding the protein components of the signal-
ing pathways involved in gastrulation, differentiation 
during ontogenesis, as well as in the self-renewal and 
differentiation of ESCs in culture. Among these genes, 
there are components of signaling pathways triggered 
by TGFβ, BMP, WNT, and FGF. SUZ12 is localized in 
distinct promotor regions, as well as in extended sites 
encompassing several genes belonging to one signal-
ing pathway, such as WNT (WNT1, WNT2, WNT6) and 
TGFβ (BMP2, GDF6). Earlier, these signaling pathways 
were proven to participate in the regulation of self-
renewal and pluripotency in murine and human ESCs 
[46]. Hence, PRC2 can directly influence ESC properties 
by regulating the components of these signaling path-
ways. However, the later data suggest maintenance of 
pluripotency in mESCs bearing the mutant EED [125]. 
ESCs bearing the homozygous EED mutation express 
OCT4 and NANOG and form chimeras. Although this 
work was a failure in its attempt to obtain adult chi-
meric mice, a large extent of chimerization was ob-
served in 12.5 day-old embryos. An attempt to obtain 
a culture of embryonic fibroblast descendants of the 
mutant ESCs failed, likely due to the low viability of 
differentiated mutant cells. Chimeric embryos (with a 
high percentage of chimerization) also had several de-
fects, such as hypertrophy of allantois and underdevel-
oped neuroectoderm and embryonic mesoderm, which 
possibly caused embryo death at the stage of about 10.5 
days after fertilization [125].
A high frequency of SUZ12 co-localization with the 
already-mentioned HCNE (bivalent chromatin domains 
are localized in HCNE-enriched regions) is an interest-
ing regularity described by Lee and colleagues [124]. 
Approximately 8% of the 14,000 HCNEs discovered 
earlier [126] are enriched in SUZ12, and the more evo-
lutionary conserved the element, the higher the level 
of enrichment [124].
Besides, one-third of the genes regulating develop-
ment and binding to PRC2 are also under the control 
of at least one of the three transcription factors, OCT4, 
SOX2, or NANOG, which are the key factors in the sys-
tem of murine and human ESC pluripotency mainte-
nance [22, 124]. These genes (such as ESX1L, ONECUT1, 
HAND1, and HOXB1) are involved in the development of 
extraembryonic tissues, as well as the ecto-, meso-, and 
endoderm. The transcription factors comprising the sys-
tem of pluripotency maintenance can directly regulate 
the genes encoding PRC2 components. So, the transcrip-
tion factors OCT4 and STAT3 (the activity of the latter 
depends on the presence of interleukin LIF) are positive 
regulators of the Eed gene in mESCs [127]. At the same 
time, OCT4 is a negative regulator of the Hdac4 gene 
encoding histone deacetylase in mESCs [128]. These fac-
tors are examples of collaboration between the system of 
epigenetic regulation of gene expression and the system 
of ESC pluripotency maintenance.
The genes implicated in the maintenance of ESC 
pluripotency and self-renewal are subjected to epige-
netic alterations during differentiation in embryogen-
esis and during induced or spontaneous differentiation 
in vitro. The Oct4 gene slightly differs from other genes 
(Dppa3/Stella/PGC7, Nanog, and Sox2) with expres-
sion typical of pluripotent cells in its mechanism of epige-
netic silencing during differentiation [129]. The labels of 
inactive chromatin, namely H4K9 methylation, and the 
presence of the HP1 heterochromatin protein are typi-
cal of the Oct4 promotor region in differentiated cells of 
P19 embryonic carcinoma and post-implantation murine 
embryos. The same type of epigenetic silencing is ob-
served in the Rex1 gene, whose transcription is positive-
ly regulated by OCT4 (this mechanism was not observed REVIEWS
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in the Nanog and Sox2 genes). The presence of H3K9me 
and HP1 favors the de novo recruiting of DNMT3A and 
DNMT3B, two DNA-methyltransferases methylating 
the promotor region of the Oct4 gene, which is neces-
sary for complete and stable transcription suppression. 
DNA methylation is the secondary process in relation 
to H3K9 methylation; a fact proven when studying the 
differentiation of mESCs bearing homozygous mutations 
of the gene encoding G9a histone methyltransferase and 
the genes Dnmt3a and Dnmt3b encoding DNA-methyl-
transferases. It was also shown recently that mutations 
interferring with H3K9 and DNA methylation inhibit 
ESC differentiation [129].
The necessary presence of euchromatin proteins in 
the sustenance of mESC pluripotency was established 
recently [130]. Repression of Chd1 gene transcription 
suppresses both ESC cell culture growth and Oct4 gene 
promotor activity. This gene encodes the euchromatin 
protein, which is co-localized with the H3K4me3 label 
of active chromatin and RNA-polymerase II in mESCs. 
Suppression of Chd1 transcription results in elevated 
expression of neural markers in ESCs and impairment 
of cell differentiation into primitive endoderm and, as 
a consequence, into cardial mesoderm descendants. At 
that stage, the ectodermal type of differentiation oc-
curs normally. Besides, Chd1 suppression drastically 
reduces the efficacy of iPSC production from embry-
onic fibroblasts [130]. Note that the transcription fac-
tors, such as OCT4, SOX2, NANOG, SMAD1, ZFX, and 
E2F1, required for the maintenance of cell pluripotency 
are localized within the Chd1 gene in ESCs [131].
The link between pluripotency and epigenetic mech-
anisms can be tracked in experiments on murine and 
human iPSC production. Several studies have demon-
strated that specific inhibitors of the enzymes implicat-
ed in the epigenetic modification of histones and DNA 
substantially increase the efficacy of iPSC production 
and can even substitute some “factors of pluripotency.” 
Currently, similar properties are known for the inhibi-
tors of histone deacetylases (valproic acid (VPA), tri-
chostatin A (TSA), and suberoylanilide hydroxamic 
acid (SAHA)) [132, 133], G9a histone methyltransferase 
inhibitor BIX-01294 [134, 135], and DNA methyltrans-
ferase inhibitors 5-azacytidine and RG108 [132–136]. 
Besides, the use of RNA interference against Dnmt in-
creases the efficacy of reprogramming due to the en-
hancement of partially reprogrammed cell transitions 
to a completely reprogrammed state [136]. Numerous 
studies devoted to the production of iPSCs of human 
and other animals have demonstrated that reprogram-
ming somatic cells to the pluripotent state is accompa-
nied by DNA demethylation in the promoter regions of 
Oct4 and Nanog, whereas they are hypermethylated in 
murine somatic cells and TSCs [137, 138].
miRNAs AND PLURIPOTENCY
Numerous studies indicate that miRNAs play an impor-
tant role in the regulation of the expression of multiple 
genes during embryo development. In particular, a mu-
tation in the Dicer gene encoding the RNAse involved 
in small noncoding RNA processing cause early death 
of murine embryos [139]. A similar effect is observed in 
mutants bearing the Dgcr8 gene mutation (its protein 
product comprises the Microprocessor complex, which 
is also implicated in miRNA biogenesis). ESCs with mu-
tations in the Dicer and Dgcr8 genes are characterized 
by the disturbance of both the cell cycle and ability to 
differentiate [140–142].
To date, more than 500 various miRNAs with their 
expression typical in various tissues and types of dif-
ferentiated cells are known. The expression of some 
miRNA families is restricted to undifferentiated ESCs. 
In murine ESCs, these families are mir-290 (mir-290, 
mir-291a, mir-291b, mir-292, mir-293, mir-294, and 
mir-295) and mir-302 cluster (mir-302a, mir-302b, 
mir-302c, mir-302d, and mir-367). In human ESCs, ex-
pression of mir-302 family miRNAs occurs, as well as 
mir-371 (mir-371, mir-372, and mir-373), whose repre-
sentatives are homologous to those of murine mir-290 
[143].
To date, the data in numerous experiments support 
the notion of a tight interaction between the system of 
miRNA-mediated regulation of gene expression and 
the system of transcription factors of pluripotency, in-
cluding OCT4, NANOG, and SOX2. Transcription fac-
tors can regulate the transcription of distinct genes and 
whole miRNA clusters, whereas miRNAs are capable 
of regulating Oct4, Nanog, and Sox2 expression at the 
posttranscriptional level [22, 23, 143]. For instance, mir-
134, mir-296, and mir-470, whose expression is elevated 
under induced differentiation of mESCs, can regulate 
Oct4, Nanog, and Sox2 in various combinations, causing 
a decrease in the levels of the corresponding proteins 
[144]. An increase in the mir-134 transcription level 
can induce mESC differentiation via the ectodermal 
pathway. The mRNAs of the Nanog and LRH1 genes, 
whose protein products positively regulate the Oct4 
gene, are the targets of mir-134 [145]. It was shown 
later that mir-200c, mir-203, and mir-183 miRNAs can 
co-repress Sox2 and Klf4, which is also required for the 
maintenance of mESC pluripotency [146]. Induction of 
this miRNA decreases the capability of self-renewal 
and leads to the induction of differentiation markers. 
In hESCs, the miRNA named mir-145 is also found. 
Its activation induces differentiation. The OCT4 tran-
scription factor represses the transcription of mir-145 
in nondifferentiated hESCs [147].
Localization of transcription factors in the human 
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genes encoding miRNAs are among the targets of 
OCT4, SOX2, and NANOG [22, 23].
Highly precise distribution mapping of the transcrip-
tion factors OCT4, SOX2, NANOG, and TCF3 in mESCs 
has shown that these transcription factors are co-local-
ized within 55 miRNA loci, including three polycistron-
ic clusters comprising 20% of all annotated mammalian 
miRNAs [143]. These miRNAs include both those that 
are actively transcribed in ESCs, as well as silencing 
forms. Hence, the transcription factors of pluripotency 
can act as activators and repressors of miRNA tran-
scription in ESCs. Besides, polycomb proteins execut-
ing di- and trimethylation of histone H3 at position K27 
(the label of inactive chromatin) are found in the pro-
moter regions of the miRNA genes repressed by OCT4, 
SOX2, NANOG, and TCF3 (Fig. 3). Transcription rear-
rangement occurs under cell differentiation, resulting 
in the formation of specific patterns of miRNA expres-
sion in each of the differentiated cell types [143].
Apparently, miRNA can be implicated in cell repro-
gramming as well. It was shown that ESC-specific mir-
291-3p, mir-294, and mir-295 miRNAs can increase the 
efficacy of murine iPSC production without the use of 
c-Myc [148]. Besides, human iPSCs have been success-
fully produced using ectopic expression of the OCT4, 
SOX2, KLF4, and LIN28 genes. The protein product of 
the LIN28 gene inhibits the production of let-7 family 
miRNA, which participates in cell differentiation [149].
TRANSCRIPTION FACTORS OCT4, Sox2, AND 
NANOG AND X-CHROMOSOME INACTIVATION
The system that sustains cell pluripotency self-renew-
al with OCT4, SOX2, and NANOG playing the central 
role is associated with the fundamental genetic proc-
esses that occur in early embryogenesis in mammals, 
particularly, X-chromosome inactivation.
In females of higher mammals, one of two geneti-
cally equivalent X-chromosomes undergoes inactiva-
tion, which is heterochromatinization and transcription 
silencing of most of its genes. The inactivation process 
consists of several studies and is managed by a complex 
genetic locus, the inactivation center, localized in the X-
chromosome [150]. Imprinted inactivation is observed 
in all murine embryo blastomers at very early devel-
opmental stages; i.e., exclusively the male-derived X-
chromosome undergoing inactivation. Reactivation of 
the inactivated X-chromosome occurs after separation 
from ICM, a pluripotent compartment of the blastocyst. 
The imprinted inactivation is retained in extraembry-
onic tissues, whereas random inactivation of the X-
chromosome becomes established in epiblast cells under 
differentiation. Xist and Tsix, which are transcribed an-
tisenses to Xist from a complementary DNA strand, are 
two genes of the inactivation center that play a crucial 
role in X-inactivation [151–153] (Fig. 4). Both genes en-
code nontranslated nuclear RNAs. The RNA of the Xist 
gene spreads along the X-chromosome, triggering the 
inactivation. Tsix transcription has a suppressing effect 
on the transcription of the Xist gene [152].
Both X-chromosomes are active in both ESCs and 
ICM cells, in which the level of Xist RNA is extremely 
low [154]. Fluorescence in situ hybridization (FISH) al-
lows to visualize the Xist transcript as a shining dot on 
each X-chromosome. Random inactivation of one par-
ent X-chromosome occurs during ESC differentiation, 
like in embryonic epiblast cells after the implantation 
into the uterus. Therefore, an obvious correlation be-
tween pluripotency and X-chromosome inactivation 
exists in female mammal cells. The molecular origin of 
this correlation was not elucidated until recently.
A link was recently found between OCT4, SOX2, and 
NANOG. It appears to play a key role in the mainte-
nance of ESC pluripotency and X-chromosome inacti-
vation [155]. OCT4, SOX2, and NANOG proteins collec-
tively bind to a DNA site in the first intron of the Xist 
gene, followed by the suppression of its transcription 
Fig. 3. miRNA genes associated with transcription factors 
OCT4, SOX2, NANOG, and TCF3 (indicated by arrows) 
and co-regulated by these factors and PRC2 (SUZ12) in 
murine and human embryonic stem cells [143].
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in undifferentiated mESCs (Fig. 4). Reversible, limited 
activation of the Xist gene is observed in ESCs bearing 
a homozygous mutation of the Nanog gene, while nor-
mal binding of OCT4 and SOX2 proteins occurs with 
the first intron of Xist. Repression of all three factors–
OCT4, SOX2, and NANOG–is accompanied by rapid 
accumulation of Xist RNA in ESC nuclei. Thus, the fac-
tors of pluripotency can directly repress the Xist gene 
via a Tsix-independent mechanism.
However, OCT4 and SOX2 have been shown to par-
ticipate in Xist gene regulation via activation of its re-
pressors, Tsix and Xite [156] (Fig. 4). A bioinformatic 
analysis has revealed one site for SOX2 binding and 
two sites for OCT4 binding in the inactivation center of 
the murine X-chromosome. One site of OCT4 binding 
is mapped to the vicinity of the CTCF and YY1 (E site) 
binding sites, at a distance of 1 kb from the DXPas34 
regulatory element, which also contains several sites 
for CTCF and YY1 binding (D site). A composite site for 
the binding of the OCT4 and SOX2 transcription factors 
was found within the region of 1.2 kb, which is known 
as the Xite enhancer (Fig. 4). The fact of OCT4 binding 
with the sequence of the E site, as well as the OCT4 and 
SOX2 factors binding to the Xite nucleotide sequence, 
was confirmed in vitro by gel-retardation and in vivo 
by chromatin immunoprecipitation methods. The Xite 
enhancer region containing the native OCT4 and SOX2 
sites can substantially enhance the activity of the major 
promoter of the Tsix gene within the luciferase report-
er gene constructs temporarily transfected into mESCs. 
Mutations in the OCT4 and SOX2 sites substantially 
decrease the capability of the Xite enhancer of Tsix 
promotor activation. Suppression of Oct4 gene expres-
sion by RNA-interference causes a substantial decrease 
in the levels of Tsix and Xite RNA in female-derived 
mESCs. Suppression of Sox2 expression also slightly 
increased the levels of Tsix and Xite RNA. Apparently, 
SOX2 plays a substantially less significant role in Tsix 
transactivation, compared to OCT4. 
Apart from protein-DNA interactions, the transcrip-
tion factors OCT4 and SOX2 are characterized by pro-
tein-protein interactions, which are directly associated 
with the X-chromosome inactivation process: OCT4 
interacts with the CTCF protein, while SOX2 interacts 
with the YY1 protein (Fig. 4). It was shown earlier that 
CTCF and its cofactor YY1 are involved in X-chromo-
some pairing at the stages of counting and choosing of 
the future inactive chromosomes. Suppression of Oct4 
expression in mESCs disturbs the X-chromosome pair-
ing in the same way as was observed under  Ctcf re-
pression, where the fall in the level of Sox2 expression 
has no significant effect on this process. Aberrant bial-
lelic Xist expression was observed during the formation 
of embryoid bodies from ESCs, with suppressed Oct4 
expression; this might be a result of the impairment of 
the X-chromosome counting process. Biallelic expres-
sion of Xist was not observed under suppression of Ctcf 
and Sox2 expression [156].
Taking into account the data in the two studies men-
tioned above, one could assume that OCT4 regulates 
the Xist gene in two ways: direct repression – together 
with SOX2 and NANOG – of Xist transcription and ac-
tivation of the Tsix gene. During cell differentiation, 
the OCT4 factor, in cooperation with CTCF, mediates 
normal X-chromosome pairing in the Tsix/Xite region, 
providing counting and choice of the future active and 
inactive X-chromosomes. The decrease in the Oct4 gene 
transcription level results in the loss of OCT4 binding 
with one of the X-chromosomes, repression of  Tsix, 
and activation of Xist, and it is the chromosome that 
becomes inactive. Yet, the residual amount of OCT4 
in the coming active X-chromosome supports Tsix ex-
pression and Xist repression. This model very elegantly 
represents the association between pluripotency and 
the status of the X-chromosome in the cells of female 
mammals. However, a number of unanswered ques-
tions still remain. For instance, how is the difference 
in the binding force or in the amounts of OCT4, SOX2, 
Fig. 4. Scheme of the 
mouse Xist/Tsix locus 
with the binding sites of 
OCT4, SOX2, and NA-
NOG, and YY1 and CTCF 
proteins interacting with 
these transcription fac-
tors. Xist and Tsix exons 
are indicated by blue and 
green rectangles, respec-
tively. The red rectangle 
represents enhancer Xite. 
Arrows indicate the direc-
tions of gene transcrip-
tion.
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and NANOG in the coming active and inactive X-chro-
mosomes achieved during differentiation. Logically, 
one should expect that, under random X-chromosome 
inactivation, this is a random process as well. But the 
question of what happens with imprinted inactivation 
when only a male-derived X-chromosome becomes in-
active arises. Active and inactive X-chromosomes are 
genetically equivalent; meaning that the difference in 
protein binding cannot be ascribed to the difference 
in nucleotide sequences. There is an evident need for 
a search for additional protein molecules or epigenetic 
factors capable of modulating this process.
Another interesting question is associated with the 
status of the X-chromosome in human ESCs. The first 
produced hESC line (H9) possessed two active X-chro-
mosomes, as was observed in mESCs [15, 157], and was 
devoid of XIST gene transcription. Random inactivation 
of one of the X-chromosome and an increase in XIST 
expression were observed during H9 differentiation. 
However, it was found later that several H9 subclones 
had the ability to express XIST, whose RNA covers the 
inactive chromosome even in nondifferentiated cells 
[158]. Moreover, other hESC lines were found to ex-
press XIST and to bear the inactive X-chromosome 
[157–159]. The data published by the International 
Consortium of Stem Cell Networks demonstrates that 
about half of the analyzed ESC lines produced in differ-
ent laboratories express the XIST gene, simultaneously 
with pluripotency markers, such as OCT4, SOX2, and 
NANOG [159]. The analysis of eleven human ESC lines 
carried out by Silva and associates [160] has enabled to 
separate ESC into three groups: 1) cells with two active 
X-chromosomes, one of which is inactivated during the 
differentiation process; 2) cells with one inactive chro-
mosome in both the undifferentiated and differentiated 
states; and 3) cells which do not express XIST in both 
the undifferentiated and differentiated states [160]. 
Further experiments have shown that, in spite of the 
lack of XIST transcription, the cells belonging to the 
third group have an inactive X-chromosome [160]. All 
of the examples given above suggest that, in humans, 
XIST transcription and X-chromosome inactivation are 
not directly associated with pluripotency and the activ-
ity of OCT4, SOX2, and NANOG.
CONCLUSION
Embryonic stem cells are a unique object for funda-
mental and applied studies. Their uniqueness is rooted 
in two of their properties – self-renewal and pluripo-
tency. Modern methods in cell biology and molecular 
genetic analysis have allowed to look anew at the mo-
lecular basis of and factors controlling self-renewal and 
pluripotency. The basic properties of embryonic stem 
cells are determined by a complex multicomponent 
system including transcription factors, signaling cas-
cades, as well as a system of epigenetic regulation and 
miRNAs. Certainly, the obtained information will help 
to better understand the nature of many processes oc-
curring in the embryogenesis of animals, including hu-
mans. Additionally, new knowledge will allow a more 
effective use of ESC in applied research, as well as to 
understand the causes behind many inherited human 
diseases and facilitate the development of therapies. 
This work was supported by the Program of the RAS 
Presidium Molecular and Cellular Biology.
REFERENCES
1. Surani M.A., Hayashi K., Hajkova P. // Cell. 2007. V. 128. 
P. 747–762.
2. Jaenisch R., Young R. // Cell. 2008. V. 132. P. 567–582.
3. Durcova-Hills G., Ainscough J., McLaren A. // Differen-
tiation. 2001. V. 68. P. 220–226.
4. McLaren A., Durcova-Hills G. // Reprod. Fertil. Dev. 2001. 
V. 13. P. 661–664.
5. Tesar P.J., Chenoweth J.G., Brook F.A., et al. // Nature. 
2007. V. 448. P. 196–199.
6. Takahashi K., Yamanaka S. // Cell. 2006. V. 126. P. 663–676.
7. Takahashi K., Tanabe K., Ohnuki M., et al. // Cell. 2007. 
V. 131. P. 861–872.
8. Wernig M., Meissner A., Foreman R., et al. // Nature. 2007. 
V. 448. P. 318–324.
9. Johnson M.H., Ziomek C.A. // Cell. 1981. V. 24. P. 71–80.
10. Zernicka-Goetz M. // Nat. Rev. Mol. Cell Biol. 2005. V. 6. 
P. 919–928.
11. Rossant J. // Cell. 2009. V. 138. P. 1047–1050.
12. Evans M.J., Kaufman M.H. // Nature. 1981. V. 292. P. 154–156.
13. Martin G.R. // Proc. Natl. Acad. Sci. USA. 1981. V. 78. 
P. 7634–7638.
14. Thomson A., Wojtacha D., Hewitt Z., et al. // Cloning 
Stem Cells. 2008. V. 10. P. 89–106.
15. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., et al. // 
Science. 1998. V. 282. P. 1145–1147.
16. Tanaka S., Kunath T., Hadjantonakis A.K., et al. // Sci-
ence. 1998. V. 282. P. 2072–2075.
17. Kunath T., Arnaud D., Uy G.D., et al. // Development. 
2005. V. 132. P. 1649–1661.
18. Shevchenko A.I., Demina V.V., Mazurok N.A., et al. // Rus. 
J. Genetics. 2008. V. 44. P. 1280-1289. 
19. Xu R.H., Chen X., Li D.S., et al. // Nat. Biotechnol. 2002. 
V. 20. P. 1261–1264.
20. Xu R.H., Peck R.M., Li D.S., et al. // Nat. Methods. 2005. 
V. 2. P. 185–190.
21. Humphrey R.K., Beattie G.M., Lopez A.D., et al. // Stem 
Cells. 2004. V. 22. P. 522–530.
22. Boyer L.A., Lee T.I., Cole M.F., et al. // Cell. 2005. V. 122. 
P. 947–956.
23. Loh Y.H., Wu Q., Chew J.L., et al. // Nat. Genet. 2006. 
V. 38. P. 431–440.
24. Niwa H., Ogawa K., Shimosato D., Adachi K. // Nature. 
2009. V. 460. P. 118–122.
25. Burdon T., Chambers I., Stracey C., et al. // Cells Tissues 
Organs. 1999. V. 165. P. 131–143.REVIEWS
 VOL. 2  № 3 (6)  2010  | ACTA NATURAE | 45
26. Smith A.G., Heath J.K., Donaldson D.D., et al. // Nature. 
1988. V. 336. P. 688–690.
27. Williams R.L., Hilton D.J., Pease S., et al. // Nature. 1988. 
V. 336. P. 684–687.
28. Niwa H., Burdon T., Chambers I., Smith A. // Genes Dev. 
1998. V. 12. P. 2048–2060.
29. Matsuda T., Nakamura T., Nakao K., et al. // EMBO J. 
1999. V. 18. P. 4261–4269.
30. Sumi T., Fujimoto Y., Nakatsuji N., Suemori H. // Stem 
Cells. 2004. V. 22. P. 861–872.
31. Shi Y., Massague J. // Cell. 2003. V. 113. P. 685–700.
32. James D., Levine A.J., Besser D., Hemmati-Brivanlou A. 
// Development. 2005. V. 132. P. 1273–1282.
33. Vallier L., Reynolds D., Pedersen R.A. // Dev. Biol. 2004. 
V. 275. P. 403–421.
34. Vallier L., Alexander M., Pedersen R.A. // J. Cell Sci. 
2005. V. 118. P. 4495–4509.
35. Assou S., Le Carrour T., Tondeur S., et al. // Stem Cells. 
2007. V. 25. P. 961–973.
36. Xiao L., Yuan X., Sharkis S.J. // Stem Cells. 2006. V. 24. 
P. 1476–1486.
37. Greber B., Lehrach H., Adjaye J. // Stem Cells. 2007. V. 25. 
P. 455–464.
38. Chen C., Ware S.M., Sato A., et al. // Development. 2006. 
V. 133. P. 319–329.
39. Levine A.J., Brivanlou A.H. // Cell Cycle. 2006. V. 5. 
P. 1069–1073.
40. Ying Q.L., Nichols J., Chambers I., Smith A. // Cell. 2003. 
V. 115. P. 281–292.
41. Amit M., Carpenter M.K., Inokuma M.S., et al. // Dev. 
Biol. 2000. V. 227. P. 271–278.
42. Hamazaki T., Kehoe S.M., Nakano T., Terada N. // Mol. 
Cell. Biol. 2006. V. 26. P. 7539–7549.
43. Dvorak P., Dvorakova D., Koskova S., et al. // Stem Cells. 
2005. V. 23. P. 1200–1211.
44. Dvorak P., Hampl A. // Folia Histochem. Cytobiol. 2005. 
V. 43. P. 203–208.
45. Aubert J., Dunstan H., Chambers I., Smith A. // Nat. 
Biotechnol. 2002. V. 20. P. 1240–1245.
46. Sato N., Meijer L., Skaltsounis L., et al. // Nat. Med. 2004. 
V. 10. P. 55–63.
47. Dravid G., Ye Z., Hammond H., et al. // Stem Cells. 2005. 
V. 23. P. 1489–1501.
48. Lu J., Hou R., Booth C.J., et al. // Proc. Natl. Acad. Sci. 
USA. 2006. V. 103. P. 5688–5693.
49. Okamoto K., Okazawa H., Okuda A., et al. // Cell. 1990. 
V. 60. P. 461–472.
50. Rosner M.H., Vigano M.A., Ozato K., et al. // Nature. 1990. 
V. 345. P. 686–692.
51. Scholer H.R., Balling R., Hatzopoulos A.K., et al. // EMBO 
J. 1989. V. 8. P. 2551–2557.
52. Palmieri S.L., Peter W., Hess H., Scholer H.R. // Dev. Biol. 
1994. V. 166. P. 259–267.
53. Nichols J., Zevnik B., Anastassiadis K., et al. // Cell. 1998. 
V. 95. P. 379–391.
54. Kirchhof N., Carnwath J.W., Lemme E., et al. // Biol. Re-
prod. 2000. V. 63. P. 1698–1705.
55. Hansis C., Grifo J.A., Krey L.C. // Mol. Hum. Reprod. 
2000. V. 6. P. 999–1004.
56. Mitalipov S.M., Kuo H.C., Hennebold J.D., Wolf D.P. // 
Biol. Reprod. 2003. V. 69. P. 1785–1792.
57. Cauffman G., van de Velde H., Liebaers I., van Steirteg-
hem A. // Mol. Hum. Reprod. 2005. V. 11. P. 173–181.
58. Niwa H., Miyazaki J., Smith A.G. // Nat. Genet. 2000. 
V. 24. P. 372–376.
59. Kehler J., Tolkunova E., Koschorz B., et al. // EMBO Rep. 
2004. V. 5. P. 1078–1083.
60. Velkey J.M., O'Shea K.S. // Genesis. 2003. V. 37. P. 18–24.
61. Hay D.C., Sutherland L., Clark J., Burdon T. // Stem Cells. 
2004. V. 22. P. 225–235.
62. Takeda J., Seino S., Bell G.I. // Nucl. Acids Res. 1992. 
V. 20. P. 4613–4620.
63. van Eijk M.J., van Rooijen M.A., Modina S., et al. // Biol. 
Reprod. 1999. V. 60. P. 1093–1103.
64. Nordhoff V., Hubner K., Bauer A., et al. // Mamm. Ge-
nome. 2001. V. 12. P. 309–317.
65. Medvedev S.P., Shevchenko A.I., Elisaphenko E.A., et al. 
// BMC Genomics. 2008. V. 9. P. 162.
66. Yeom Y.I., Ha H.S., Balling R., et al. // Mech. Dev. 1991. 
V. 35. P. 171–179.
67. Atlasi Y., Mowla S.J., Ziaee S.A., et al. // Stem Cells. 2008. 
V. 26. P. 3068–3074.
68. Lee J., Kim H.K., Rho J.Y., et al. // J. Biol. Chem. 2006. 
V. 281. P. 33554–33565.
69. Cauffman G., Liebaers I., van Steirteghem A., van de 
Velde H. // Stem Cells. 2006. V. 24. P. 2685–2691.
70. Wang X., Zhao Y., Xiao Z., et al. // Stem Cells. 2009. V. 27. 
P. 1265–1275.
71. Wang S.H., Tsai M.S., Chiang M.F., Li H. // Gene Expr. 
Patterns. 2003. V. 3. P. 99–103.
72. Chambers I., Colby D., Robertson M., et al. // Cell. 2003. 
V. 113. P. 643–655.
73. Mitsui K., Tokuzawa Y., Itoh H., et al. // Cell. 2003. V. 113. 
P. 631–642.
74. Hyslop L., Stojkovic M., Armstrong L., et al. // Stem Cells. 
2005. V. 23. P. 1035–1043.
75. Pan G.J., Pei D.Q. // Cell Res. 2003. V. 13. P. 499–502.
76. Pan G., Pei D. // J. Biol. Chem. 2005. V. 280. P. 1401–1407.
77. Mullin N.P., Yates A., Rowe A.J., et al. // Biochem. J. 2008. 
V. 411. P. 227–231.
78. Wang J., Levasseur D.N., Orkin S.H. // Proc. Natl. Acad. 
Sci. USA. 2008. V. 105. P. 6326–6331.
79. Wang Z., Ma T., Chi X., Pei D. // J. Biol. Chem. 2008. 
V. 283. P. 4480–4489.
80. Medvedev S.P., Elisaphenko E.A., Shevchenko A.I., et al. 
// Dokl. Biochem. Biophys. 2009. V. 425. P. 102–105.
81. Avilion A.A., Nicolis S.K., Pevny L.H., et al. // Genes Dev. 
2003. V. 17. P. 126–140.
82. Masui S., Nakatake Y., Toyooka Y., et al. // Nat. Cell Biol. 
2007. V. 9. P. 625–635.
83. Adachi K., Suemori H., Yasuda S.Y., et al. // Genes Cells. 
2010. V. 15. P. 455–470.
84. Botquin V., Hess H., Fuhrmann G., et al. // Genes Dev. 
1998. V. 12. P. 2073–2090.
85. Yuan H., Corbi N., Basilico C., Dailey L. // Genes Dev. 
1995. V. 9. P. 2635–2645.
86. Nishimoto M., Fukushima A., Okuda A., Muramatsu M. 
// Mol. Cell. Biol. 1999. V. 19. P. 5453–5465.
87. Liu L., Roberts R.M. // J. Biol. Chem. 1996. V. 271. 
P. 16683–16689.
88. Liu L., Leaman D., Villalta M., Roberts R.M. // Mol. Endo-
crinol. 1997. V. 11. P. 1651–1658.
89. Pesce M., Scholer H.R. // Mol. Reprod. Dev. 2000. V. 55. 
P. 452–457.
90. Ambrosetti D.C., Basilico C., Dailey L. // Mol. Cell. Biol. 
1997. V. 17. P. 6321–6329.
91. Tomilin A., Remenyi A., Lins K., et al. // Cell. 2000. V. 103. 
P. 853–864.
92. Remenyi A., Tomilin A., Pohl E., et al. // Mol. Cell. 2001. 
V. 8. P. 569–580.46 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
REVIEWS
93. Kang J., Gemberling M., Nakamura M., et al. // Genes 
Dev. 2009. V. 23. P. 208–222.
94. Abeyta M.J., Clark A.T., Rodriguez R.T., et al. // Hum. 
Mol. Genet. 2004. V. 13. P. 601–608.
95. Brandenberger R., Khrebtukova I., Thies R.S., et al. // 
BMC Dev. Biol. 2004. V. 4. P. 10.
96. Catena R., Tiveron C., Ronchi A., et al. // J. Biol. Chem. 
2004. V. 279. P. 41846–41857.
97. Kuroda T., Tada M., Kubota H., et al. // Mol. Cell. Biol. 
2005. V. 25. P. 2475–2485.
98. Niwa H. // Cell Struct. Funct. 2001. V. 26. P. 137–148.
99. Okumura-Nakanishi S., Saito M., Niwa H., Ishikawa F. // 
J. Biol. Chem. 2005. V. 280. P. 5307–5317.
100. Rodda D.J., Chew J.L., Lim L.H., et al. // J. Biol. Chem. 
2005. V. 280. P. 24731–24737.
101. Sato N., Sanjuan I.M., Heke M., et al. // Dev. Biol. 2003. 
V. 260. P. 404–413.
102. Wei C.L., Miura T., Robson P., et al. // Stem Cells. 2005. 
V. 23. P. 166–185.
103. Chew J.L., Loh Y.H., Zhang W., et al. // Mol. Cell. Biol. 
2005. V. 25. P. 6031–6046.
104. Suzuki A., Raya A., Kawakami Y., et al. // Proc. Natl. 
Acad. Sci. USA. 2006. V. 103. P. 10294–10299.
105. Wang J., Rao S., Chu J., et al. // Nature. 2006. V. 444. 
P. 364–368.
106. Wu Q., Chen X., Zhang J., et al. // J. Biol. Chem. 2006. 
V. 281. P. 24090–24094.
107. Pardo M., Lang B., Yu L., et al. // Cell Stem Cell. 2010. 
V. 6. P. 382–395.
108. van den Berg D.L., Snoek T., Mullin N.P., et al. // Cell 
Stem Cell. 2010. V. 6. P. 369–381.
109. Hatano S.Y., Tada M., Kimura H., et al. // Mech. Dev. 
2005. V. 122. P. 67–79.
110. Lauberth S.M., Rauchman M. // J. Biol. Chem. 2006. 
V. 281. P. 23922–23931.
111. Korutla L., Wang P.J., Mackler S.A. // J. Neurochem. 
2005. V. 94. P. 786–793.
112. Tomioka M., Nishimoto M., Miyagi S., et al. // Nucleic 
Acids Res. 2002. V. 30. P. 3202–3213.
113. Brehm A., Ohbo K., Zwerschke W., et al. // Mol. Cell. 
Biol. 1999. V. 19. P. 2635–2643.
114. Guo Y., Costa R., Ramsey H., et al. // Proc. Natl. Acad. 
Sci. USA. 2002. V. 99. P. 3663–3667.
115. Tolkunova E., Malashicheva A., Parfenov V.N., et al. // J. 
Mol. Biol. 2007. V. 374. P. 1200–1212.
116. Webster D.M., Teo C.F., Sun Y., et al. // BMC Dev. Biol. 
2009. V. 9. P. 28.
117. Bernstein B.E., Mikkelsen T.S., Xie X., et al. // Cell. 2006. 
V. 125. P. 315–326.
118. Ringrose L., Paro R. // Annu. Rev. Genet. 2004. V. 38. 
P. 413–443.
119. O'Carroll D., Erhardt S., Pagani M., et al. // Mol. Cell. 
Biol. 2001. V. 21. P. 4330–4336.
120. Pasini D., Bracken A.P., Jensen M.R., et al. // EMBO J. 
2004. V. 23. P. 4061–4071.
121. Shumacher A., Faust C., Magnuson T. // Nature. 1996. 
V. 383. P. 250–253.
122. Voncken J.W., Roelen B.A., Roefs M., et al. // Proc. Natl. 
Acad. Sci. USA. 2003. V. 100. P. 2468–2473.
123. Boyer L.A., Plath K., Zeitlinger J., et al. // Nature. 2006. 
V. 441. P. 349–353.
124. Lee T.I., Jenner R.G., Boyer L.A., et al. // Cell. 2006. 
V. 125. P. 301–313.
125. Chamberlain S.J., Yee D., Magnuson T. // Stem Cells. 
2008. V. 26. P. 1496–1505.
126. Woolfe A., Goodson M., Goode D.K., et al. // PLoS Biol. 
2005. V. 3. P. e7.
127. Ura H., Usuda M., Kinoshita K., et al. // J. Biol. Chem. 
2008. V. 283. P. 9713–9723.
128. Addis R.C., Prasad M., Yochem R.L., et al. // J. Cell. Bio-
chem. 2010. [Epub ahead of print] 
129. Feldman N., Gerson A., Fang J., et al. // Nat. Cell Biol. 
2006. V. 8. P. 188–194.
130. Gaspar-Maia A., Alajem A., Polesso F., et al. // Nature. 
2009. V. 460. P. 863–868.
131. Chen X., Xu H., Yuan P., et al. // Cell. 2008. V. 133. 
P. 1106–1117.
132. Huangfu D., Maehr R., Guo W., et al. // Nat. Biotechnol. 
2008. V. 26. P. 795–797.
133. Huangfu D., Osafune K., Maehr R., et al. // Nat. Biotech-
nol. 2008. V. 26. P. 1269–1275.
134. Shi Y., Desponts C., Do J.T., et al. // Cell Stem Cell. 2008. 
V. 3. P. 568–574.
135. Shi Y., Do J.T., Desponts C., et al. // Cell Stem Cell. 2008. 
V. 2. P. 525–528.
136. Mikkelsen T.S., Hanna J., Zhang X., et al. // Nature. 
2008. V. 454. P. 49–55.
137. Hattori N., Nishino K., Ko Y.G., et al. // J. Biol. Chem. 
2004. V. 279. P. 17063–17069.
138. Hattori N., Imao Y., Nishino K., et al. // Genes Cells. 
2007. V. 12. P. 387–396.
139. Bernstein E., Kim S.Y., Carmell M.A., et al. // Nat. Genet. 
2003. V. 35. P. 215–217.
140. Kanellopoulou C., Muljo S.A., Kung A.L., et al. // Genes 
Dev. 2005. V. 19. P. 489–501.
141. Murchison E.P., Partridge J.F., Tam O.H., et al. // Proc. 
Natl. Acad. Sci. USA. 2005. V. 102. P. 12135–12140.
142. Wang Y., Medvid R., Melton C., et al. // Nat. Genet. 2007. 
V. 39. P. 380–385.
143. Marson A., Levine S.S., Cole M.F., et al. // Cell. 2008. 
V. 134. P. 521–533.
144. Tay Y., Zhang J., Thomson A.M., et al. // Nature. 2008. 
V. 455. P. 1124–1128.
145. Tay Y.M., Tam W.L., Ang Y.S., et al. // Stem Cells. 2008. 
V. 26. P. 17–29.
146. Wellner U., Schubert J., Burk U.C., et al. // Nat. Cell Biol. 
2009. V. 11. P. 1487–1495.
147. Xu N., Papagiannakopoulos T., Pan G., et al. // Cell. 2009. 
V. 137. P. 647–658.
148. Judson R.L., Babiarz J.E., Venere M., Blelloch R. // Nat. 
Biotechnol. 2009. V. 27. P. 459–461.
149. Yu J., Vodyanik M.A., Smuga-Otto K., et al. // Science. 
2007. V. 318. P. 1917–1920.
150. Chureau C., Prissette M., Bourdet A., et al. // Genome 
Res. 2002. V. 12. P. 894–908.
151. Brockdorff N., Ashworth A., Kay G.F., et al. // Cell. 1992. 
V. 71. P. 515–526.
152. Lee J.T., Davidow L.S., Warshawsky D. // Nat. Genet. 
1999. V. 21. P. 400–404.
153. Lee J.T., Lu N. // Cell. 1999. V. 99. P. 47–57.
154. Wutz A., Jaenisch R. // Mol. Cell. 2000. V. 5. P. 695–705.
155. Navarro P., Chambers I., Karwacki-Neisius V., et al. // 
Science. 2008. V. 321. P. 1693–1695.
156. Donohoe M.E., Silva S.S., Pinter S.F., et al. // Nature. 
2009. V. 460. P. 128–132.
157. Dhara S.K., Benvenisty N. // Nucleic Acids Res. 2004. 
V. 32. P. 3995–4002.
158. Hoffman L.M., Hall L., Batten J.L., et al. // Stem Cells. 
2005. V. 23. P. 1468–1478.
159. Adewumi O., Aflatoonian B., Ahrlund-Richter L., et al. 
// Nat. Biotechnol. 2007. V. 25. P. 803–816.
160. Silva S.S., Rowntree R.K., Mekhoubad S., Lee J.T. // 
Proc. Natl. Acad. Sci. USA. 2008. V. 105. P. 4820–4825.